Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

Désirée van der Heijde, Dennis A. Revicki, Katherine Gooch, Robert Wong, H. Küpper, Neesha Harnam, Chris Thompson, Joachim Sieper

Arthritis Research & Therapy · 2009 · 88 citations · 42 references

DOIFull text

Open access

Abstract

Adalimumab significantly improved disease activity, patient-reported physical function, and HRQOL. These benefits were maintained over three years of treatment in patients with AS.

References

42